GCG and heart failure: The second study, called LIVE (Effect of Liraglutide, a Glucagon-like Peptide‐1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients With and Without Diabetes), included 241 patients with stable heart failure and found no significant change in LVEF after 24 weeks of treatment with liraglutide versus placebo (mean difference −0.8% (95% CI −2.1% to 0.5%)).